Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq:APTO; TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company’s Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company’s lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatment of newly diagnosed AML patients.